Novavax says its coronavirus vaccine was 89% effective in a UK trial, but it didn't work nearly as well in a second studyBusiness Insider • 01/28/21
Novavax Stock Surges After Covid Vaccine Proves Nearly 90% EffectiveInvestors Business Daily • 01/28/21
Novavax stock soars more than 20% after COVID-19 vaccine study shows nearly 90% efficacy in UK, less against new South African variantMarket Watch • 01/28/21
Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 VaccineGlobeNewsWire • 01/22/21
Novavax Names Madelyn Caltabiano Senior Vice President, Global Program ManagementGlobeNewsWire • 01/22/21